ClinicalTrials.gg
RecruitingNCT06628271BAMUpdated May 5, 2026

Breath-holding Spells and Its Management Study

An interventional study of Guidelines in Breath-holding Spell, sponsored by Region Skane. Recruiting at 12 sites in Sweden. Open to participants aged 0 Months to 60 Months. Per ClinicalTrials.gov, last updated 2026-05-05.

Sponsored by Region Skane · Not applicable, Interventional, and Diagnostic

How we know

From the registry’s dates

  • Started Dec 2024; still recruiting 1 year 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
120
Allocation
Non-randomized
Ages
0 Months to 60 Months
Sex
All
01

Study summary

The goal of this prospective population-based study is to evaluate the new disease description and management guidelines for breath-holding spells in children (Hellström Schmidt et al, Acta Paediatrica 2024) below the age of 5 years in southern Sweden. The main questions it aims to answer are:

  • Does the disease description and management guidelines lead to the expected reduction in diagnostic interventions and are the clinical managements guidelines safe to use?
  • If iron supplementation is given, does it reduce the frequency and severity of the spells?
  • What information and support does parents to children with breath-holding spells need?

Participants will undergo evaluation by a medical doctor and if typical breath-holding spells are diagnosed, be managed according to the new guidelines. If iron deficiency is found, iron supplementation is recommended. Digital surveys will be distributed and parents of patients with frequent spells will be eligible for participation in an interview sub-study.

Read the detailed description

Please see the Study plan among the documents.

02

Conditions studied

  • Breath-holding Spell

Keywords

  • disease definition
  • electrocardiography
  • iron deficiency anemia
  • long QT syndrome
  • parental support
03

In context

Anemia, Iron-Deficiency

602 studies on the registry are indexed under Anemia, Iron-Deficiency; 93 are open to participants now.

This study's planned enrollment of 120 is above the median of 100 across 461 interventional studies indexed under Anemia, Iron-Deficiency.

Browse Anemia, Iron-Deficiency studies →

Lead sponsor

Region Skane is the lead sponsor of 386 studies on the registry; 122 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
0 Months to 60 Months
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Below 5 years of age
  • resident in Region Skåne (Sweden)
  • suspected breath-holding spell

Exclusion criteria

Exclusion Criteria:

  • previous investigation for breath-holding spell (previous spells are not a reason for exclusion)
05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
120 participants (estimated)

Study arms

  • Other
    Typical spells

    Patients with typical spells should be investigated according to our guidelines

    Diagnostic Test: Guidelines

  • No intervention
    Non-typical spells

    Patients with non-typical spells will be investigated individually, as it is done today

Interventions

  • Diagnostic testGuidelines

    Participant with typical spells will be investigated according to our guidelines. These include that participants with heredity for or signs and symptoms of cardiac disease will be subjected to an ECG and participants with two or more spells should be subjected to blood tests for anemia and iron deficiency

06

What researchers measure

Primary outcomes

  1. Safety of the guidelines

    The number of wrongful and missed diagnoses (definition: managed and diagnosed as breath-holding spells at physician assessment within study but later found to be another cause for the symptoms, like long QT syndrome or epilepsy).

    Time frame: From date of inclusion to end of follow up at 36 months

  2. Usability of the guidelines

    Assessed according to the following: * Number of patients with a diagnostic interventions for each intervention in the guidelines: ECGs and bloodtests. * Number of found pathologies for each intervention (blood tests and ECGs) - for patients with typical spells handled according to the guidelines and those with non-typical spells managed individually. This includes a retrospective assessment of ECG (a complete assessment including rythm, long QT syndrome, AV-block, ST-segment changes) and blood test results (for anemia and iron deficiency; i.e. values outside of the age adapted normal range). * Retrospective analysis of the clinical doctors compliance with managment guidelines, evaluated through the number of interventions for each patient that were not recommended in the guidlines (for instance number of EEGs).

    Time frame: From date of inclusion until last diagnostic intervention, expected to be within 2 weeks from inclusion.

  3. Usability of the disease definition

    Assessed according to the following: * Adherence to the the prespecified definition of typical spells through comparison of clinical physicians assessment and a retrospective assessment by study physician, i.e. the number of cases with a discrepant judgment of the clinical presentation. * The number of typical spells compared to the number of non-typical spells and other diagnsoses. * Compilation of patient and spell characteristics (defined in the variable list in the attached documents) and comparison with the current definition of typical spells.

    Time frame: From the inclusion date until end of physicians assessment

Secondary outcomes

  1. Need of information and support to parents

    Through interview study (qualitative study) gather information on given information and support and their need for more information and support. Will be conducted on parents of children with more than 5 spells in total at the 6 month follow up (assessed as frequent spells).

    Time frame: From 6 months after inclusion until interview is performed (expected to be within three months of six month digital survey)

  2. Effect of iron supplement treatment on spell frequency and severity

    In cases of iron treatment (initiated by the clinical physician). Assessed according to the following: * Comparison of spell frequency (number of spells/time unit) before start of treatment, during treatment and after completion of treament. * Comparison of spell severity (simple or severe spells defined as spells without and with loss of consciousness) before start of treatment, during treatment and after completion of treament. * Anemia and iron deficiency blood test values (Hb, MCV, reticulocytes, ferritin, CRP if signs of infection, iron, iron saturation and transferrin) comparison between patients with effect of iron treatment on spell frequency and severity, versus the group without a clinical effect of iron treatment. * Patient compliance for iron supplementation as per survey question with answer altneratives yes/no/don't know

    Time frame: From the date of inclusion until evaluation of iron treatment, most probably within 12 months from inclusion.

Other outcomes

  1. Natural course of the spells through long term follow-up

    Assessed according to the following parameters, through digital surveys: * Spells during the last 3 months (yes or no) * Number of spells the previous month (0, 1, 2-5, 6-10, \>10) * Total number of spells (free text) * Uncontactable or unconscious (=severity of spells) (Yes, No, Don't know) * Alterations in spell semiology? (Yes, No, Don't know)

    Time frame: 36 months

  2. Contact with health care during long term follow-up

    Evaluation of the following questions: 1. Do parents follow the advice to reach out to health care if the spell semiology change? 2. Planned follow up? Above questions are assessed in a digital survey: \- Further contact with healthcare. Answer alternatives: (Yes, No, Don't know). If yes: (acute or planned)

    Time frame: 36 months

  3. Burden of care

    Will be assessed through a combined evaluation of the following variables: * Number of acute health care visits * Number of planned health care visits including follow-up appointments over phone * Number of over-night hospital stays (number of nights) * Number of ambulance rides to the hospital

    Time frame: 36 months

  4. Dietary impact on iron status

    At first visit, parents will answer questions on the child and family's diet in a questionnaire, to evaluate a possible association between diet and iron status (and further, to breath-holding spell frequency and severity). The questions are as follows: * Mark all alternatives that is correct about your childs diet: (breatmilk/formula/cow's milk/taste portions/family meals) * Does your child drink more than 3 dl of cow's milk per day? (yes/no) \> If yes, estimate the amount of cow's milk your child drink during a day in dl: (a number in free text) * Do you eat vegetarian or vegan food only? (yes/no)

    Time frame: From inclusion to blood test results, within 2 weeks from initial visit

07

Study locations

12 of 12 sites recruiting
  • Barn- och ungdomsmedicinmottagning Eslöv
    Eslöv, Sweden
    Recruiting
    • Annika Lagström · Contact
  • Capio Barnavårdscentral Kristianstad
    Kristianstad, Sweden
    Recruiting
    • Linda Nyberg · Contact
  • Barnläkargruppen Sparta
    Lund, Sweden
    Recruiting
    • Johanna Bengtsson · Contact
  • Skåne University Hospital
    Lund, Sweden
    Recruiting
    • Sanna Hellström Schmidt, MD · Contact
  • Barnläkargruppen Sparta
    Malmö, Sweden
    Recruiting
    • Johanna Bengtsson · Contact
  • BVC Bambino Hyllie
    Malmö, Sweden
    Recruiting
    • Anna Sövgren · Contact
  • BVC Bambino Lindängen
    Malmö, Sweden
    Recruiting
    • Anna Sövgren · Contact
  • BVC Bambino Mobilia
    Malmö, Sweden
    Recruiting
    • Anna Sövgren · Contact
  • Skåne University Hospital
    Malmö, Sweden
    Recruiting
    • Sanna Hellström Schmidt, MD · Contact
  • Barn- och ungdomsmedicinmottagning Simrishamn, Capio närsjukhus
    Simrishamn, Sweden
    Recruiting
    • Therése Saksø · Contact
  • Familjecentralen Björken, BVC Sjöbo
    Sjöbo, Sweden
    Recruiting
    • Gustav Robertz, MD · Contact
  • Lasarettet i Ystad
    Ystad, Sweden
    Recruiting
    • Gustav Robertz, MD · Contact
08

References and documents

Publications

  • Hellstrom Schmidt S, Smedenmark J, Jeremiasen I, Sigurdsson B, Eklund EA, Pronk CJ. Overuse of EEG and ECG in children with breath-holding spells and its implication for the management of the spells. Acta Paediatr. 2024 Feb;113(2):317-326. doi: 10.1111/apa.17020. Epub 2023 Oct 31. PubMed 37905418 ↗
  • Hellstrom Schmidt S, Tedgard U, Pronk CJ. Breath-holding spells occur disproportionately more often in children with transient erythroblastopenia. Acta Paediatr. 2016 Sep;105(9):1088-93. doi: 10.1111/apa.13428. Epub 2016 Apr 29. PubMed 27060698 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Undecided — Data will be share as far as the Swedish law (concerning patient confidentiality) and ethical considerations allows. Decisions will be made from case to case depending on what data are inquired for.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2024 (actual). Primary completion is estimated for Dec 2030, 72 months after the start.

Of 133 non-industry interventional studies with no phase under Anemia, Iron-Deficiency, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 21. This study's planned 72 months is above that.

Counting every sponsor, half of 142 studies reached it within 11 months; a quarter within 3 and three quarters within 21.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 16, 2024
First posted
Oct 4, 2024
StartActual
Dec 2, 2024
Primary completionEst.
Dec 2030
CompletionEst.
Dec 2030
Last update
May 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 5, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06628271
Lead sponsor
Region Skane
Responsible party
Sponsor
First posted
Oct 4, 2024
Start date
Dec 2, 2024
Primary completion
Dec 2030 (estimated)
Completion
Dec 2030 (estimated)
Last update
May 5, 2026

Study contacts

Sanna Hellström Schmidt, MD
Contact
sanna.hellstrom_schmidt@med.lu.se
+4646177203
Cornelis J Pronk, MD, PhD
Contact
kees-jan.pronk@med.lu.se

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion